Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSV | O60911 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11528426 | 0.94 | CTSV (0.32) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL10471228 | 0.87 | — | — | |
| SCHEMBL20236951 | 0.86 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL21025727 | 0.85 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL28517849 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6994576 | 0.85 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6994573 | 0.85 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14920912 | 0.85 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12738804 | 0.85 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12489688 | 0.85 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7518003-B2 | Production process of tetrahydropyran compound and tetrahydropyran compound produced by the production process | SHOWA DENKO K.K. (JP) | 2009-04-14 | — | — | US | claimed |
| US-20080139828-A1 | Reacting 3,4-dihydro-2-alkoxy-2H-pyran with hydrogen in the presence of a catalyst under acidic condition; Grignard reaction solvent or polymer solvent | SHOWA DENKO K.K. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1828158-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2007-09-05 | — | — | EP | claimed |
| WO-2006062211-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO K.K. (JP) | 2006-06-15 | — | — | WO | claimed |
| US-20230226002-A1 | RETINAL BIOAVAILBILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226002-A1 | RETINAL BIOAVAILBILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-07-20 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022115645-A9 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022115645-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-11318231-B2 | Anti-inflammatory coatings to improve biocompatibility of neurological implants | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220031913-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2022-02-03 | — | — | US | disclosed |
| WO-2021257636-A1 | RETINAL BIOAVAILABILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2015054103-A1 | OXAZOLIDINONES AS MODULATORS OF MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-16 | — | — | WO | disclosed |
| US-8722894-B2 | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2011011303-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7518003-B2 | Production process of tetrahydropyran compound and tetrahydropyran compound produced by the production process | SHOWA DENKO K.K. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080139828-A1 | Reacting 3,4-dihydro-2-alkoxy-2H-pyran with hydrogen in the presence of a catalyst under acidic condition; Grignard reaction solvent or polymer solvent | SHOWA DENKO K.K. (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1828158-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006062211-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO K.K. (JP) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031913-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | MEN1 4554/4885KMT2A 2618/4885KDM4C 1830/4885 |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | HDAC6, PSMG3, PSMB2 | MEN1 4269/4885KMT2A 619/4885KDM4C 2132/4885 |
| US-20100240706-A1 | 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRIN2C | MEN1 3371/4885KMT2A 1575/4885KDM4C 1966/4885 |
| US-20230226002-A1 | RETINAL BIOAVAILBILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | ELOVL1, ELOVL3, FFAR2 | MEN1 3848/4885KMT2A 3613/4885KDM4C 3982/4885 |
| US-20080139828-A1 | Reacting 3,4-dihydro-2-alkoxy-2H-pyran with hydrogen in the presence of a catalyst under acidic condition; Grignard reaction solvent or polymer solvent | HPD, ACR, GRHPR | MEN1 3558/4885KMT2A 2893/4885KDM4C 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.